GRB2

Across TCGA pan-cancer cohorts, GRB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRB2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GRB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GRB2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and OV show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where GRB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.232	0.733	.006	27	view →
HNSC	OS	Median	All	1.000	0.484	.038	24	view →
LUAD	OS	Median	III,IV	0.287	0.777	.004	6	view →
OV	DFS	Median	All	1.000	0.858	.028	4	view →
LSCC	OS	Median	All	0.933	0.838	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GRB2–CCRCC (DFS)

Open the CCRCC breakdown →